<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="case-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1376276</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A case report of IgG4-related hepatic inflammatory pseudotumor in a 3-year old boy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Zhongjin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xiaohui</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2613983"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Zhuqiang</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhong</surname>
<given-names>Qingmei</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wu</surname>
<given-names>Chongjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1177115"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Hematology, Jiangxi Provincial Children&#x2019;s Hospital</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Rheumatology and Immunology, Jiangxi Provincial Children&#x2019;s Hospital</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Nuclear Magnetic Resonance Room, Jiangxi Provincial Children&#x2019;s Hospital</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Pathology, The Ninth Hospital of Nanchang</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Alexandre Wagner Silva De Souza, Federal University of S&#xe3;o Paulo, Brazil</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Atsushi Masamune, Tohoku University, Japan</p>
<p>Yoichi Nakagawa, Nagoya University Graduate School of Medicine, Japan</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Chongjun Wu, <email xlink:href="mailto:wuchongjunmed@163.com">wuchongjunmed@163.com</email>
</p>
</fn>
<fn fn-type="other" id="fn003">
<p>&#x2020;These authors share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1376276</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Wan, Xu, Liu, Wu, Zhong and Wu</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Wan, Xu, Liu, Wu, Zhong and Wu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Hepatic Inflammatory Pseudotumor (IPT) is an infrequent condition often masquerading as a malignant tumor, resulting in misdiagnosis and unnecessary surgical resection. The emerging concept of IgG4-related diseases (IgG4-RD) has gained widespread recognition, encompassing entities like IgG4-related hepatic IPT. Clinically and radiologically, corticosteroids and immunosuppressive therapies have proven effective in managing this condition.</p>
</sec>
<sec>
<title>Case Presentation</title>
<p>A 3-year-old Chinese boy presented to the clinic with an 11-month history of anemia, fever of unknown origin, and a tender hepatic mass. Blood examinations revealed chronic anemia (Hb: 6.4 g/L, MCV: 68.6 fl, MCH: 19.5 pg, reticulocytes: 1.7%) accompanied by an inflammatory reaction and an elevated serum IgG4 level (1542.2 mg/L). Abdominal contrast-enhanced computed tomography unveiled a 7.6&#xa0;cm low-density mass in the right lateral lobe, while magnetic resonance imaging demonstrated slight hypointensity on T1-weighted images and slight hyperintensity on T2-weighted images, prompting suspicion of hepatic malignancy. A subsequent liver biopsy revealed a mass characterized by fibrous stroma and dense lymphoplasmacytic infiltration. Immunohistochemical analysis confirmed the presence of IgG4-positive plasma cells, leading to the diagnosis of IgG4-related hepatic IPT. Swift resolution occurred upon initiation of corticosteroid and mycophenolate mofetil therapies.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study underscores the diagnostic approach to hepatic IPT, utilizing histopathology, immunostaining, imaging, serology, organ involvement, and therapeutic response. Early histological examination plays a pivotal role in clinical guidance, averting misdiagnosis as a liver tumor and unnecessary surgical interventions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>hepatic inflammatory pseudotumor</kwd>
<kwd>IgG4-related disease</kwd>
<kwd>steroid</kwd>
<kwd>child</kwd>
<kwd>liver biopsy</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="42"/>
<page-count count="7"/>
<word-count count="3061"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Hepatic Inflammatory Pseudotumor (IPT) stands as an infrequent benign lesion often mistaken for a malignant tumor, leading to unnecessary surgical resections. Characterized histologically by the proliferation of fibroblasts or myofibroblasts and the presence of inflammatory cells, primarily polyclonal lymphocytes and plasma cells, Hepatic IPT accounts for approximately 8% of extrapulmonary IPT cases (<xref ref-type="bibr" rid="B1">1</xref>). With the emergence of the concept of immunoglobulin G4 (IgG4)-related hepatic IPT (<xref ref-type="bibr" rid="B2">2</xref>), interest in studying this rare condition has surged. Notably, only a handful of cases, particularly in children, have been reported, limiting our understanding of this disease (<xref ref-type="bibr" rid="B3">3</xref>). We present a unique case of IgG4-related hepatic IPT in a 3-year-old boy who sought medical attention with an 11-month history of anemia, a fever of unknown origin, and a tender hepatic mass. Previous cases, such as those reported by Al-Hussaini et&#xa0;al. (<xref ref-type="bibr" rid="B4">4</xref>)and Shibata et&#xa0;al. (<xref ref-type="bibr" rid="B5">5</xref>), underscore the challenge in accurately diagnosing hepatic IPT, often leading to recommendations for surgical interventions due to a high suspicion of malignancy. In this case, immunohistochemical analysis revealed focal positivity for IgG4, prompting consideration of IgG4-related hepatic IPT as part of the IgG4-related diseases (IgG4-RD) hepatobiliary disease spectrum (<xref ref-type="bibr" rid="B3">3</xref>). Given the rarity of this condition and the potential for misdiagnosis, we advocate for increased awareness and consideration of IgG4-related hepatic IPT in pediatric patients presenting with similar clinical features.</p>
<p>In order to avert diagnostic oversight and consequent therapeutic delay in this condition, we present a rare case of IgG4-related hepatic IPT in a 3-year-old male patient. The child sought medical attention with an 11-month history marked by anemia, a fever of unknown origin, and a tender hepatic mass. Significantly, successful resolution of the disease was achieved through a course of corticosteroid and mycophenolate mofetil therapy.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Case presentation</title>
<p>A 3-year-old male presented at the clinic with an 11-month history characterized by anemia, a fever of unknown origin, and a tender hepatic mass. Initial routine blood examination 11 months ago revealed anemia (hemoglobin 82 g/L), while abdominal Doppler ultrasound and chest X-ray results displayed no abnormalities. Notably, further investigation into the cause of anemia was not pursued at that time. Subsequently, iron supplementation was initiated, but after one month of treatment, no improvement in anemia was observed. Upon admission to our hospital, the patient exhibited hemoglobin levels of 66 g/L, prompting a thorough examination for diagnosis and treatment. Additionally, the past 3-month medical history included significant abdominal distention, interpreted as indigestion and managed with probiotics by the parents. There was no consanguinity, chronic illness, or malignancies in the family history. The physical examination was notable for tender hepatomegaly, palpable 3&#xa0;cm below the costal margin. The physical examination revealed notable pale complexion and tender hepatomegaly, palpable 3&#xa0;cm below the costal margin. Several enlarged lymph nodes were palpated on both sides of the neck, armpits, and groin, with the largest being about 2&#xd7;1cm, no rupture and acceptable mobility. Rash or subcutaneous mass were not found on the entire body skin. Swollen mass was not found in the orbit, tonsils, or nose. Bilateral parotid and submandibular glands were not enlargement. Physical examination of the heart, spleen, pancreas, and kidneys showed no abnormalities. Major vascular murmurs or abnormal breathing sounds were not found.</p>
<p>Laboratory investigations unveiled chronic iron-deficiency anemia in the patient, characterized by a hemoglobin level of 6.4 g/L, MCV of 68.6 fl, MCH of 19.5 pg, reticulocyte count of 1.7%, ferritin concentration of 87.7 ng/mL (within the normal range of 50-142 ng/mL), and a serum iron level of 5.8 &#x3bc;mol/L (normal range: 13-32 &#x3bc;mol/L). Folic acid, vitamin B12, and thalassemia gene levels were found to be within normal limits. Bone marrow cytology revealed proliferative anemia, with 1% intracellular iron and + extracellular iron.</p>
<p>Other laboratory tests showed a normal white blood cell count, renal, hepatic, coagulation profiles, a normal eosinophils number of 0.05&#xd7;10<sup>9</sup>/L, a normal eosinophil percentage of 0.4%, a high erythrocyte sedimentation rate (ESR) of 76 mm/h, a high immunoglobulin G (IgG) concentration of 60.74 g/L, a normal IgE concentration, a normal complement 3 concentration, a low complement 4 concentration of 0.11g/L, a high C-reactive protein (CRP) level of 236.5 mg/L and a high fungal D-glucan level of 974.6 pg/mL. Serological tests for hepatitis-B, syphilis, Epstein-Barr virus (EBV), and human immunodeficiency virus were negative. Tumor markers such as alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) were negative.</p>
<p>Abdominal Doppler ultrasound revealed a heterogeneous lesion measuring 9.1&#xa0;cm &#xd7; 6.6&#xa0;cm &#xd7; 6.9&#xa0;cm in the right hepatic lobe, displaying a nonspecific appearance.</p>
<p>Contrast-enhanced computed tomography (CT) of the abdomen revealed a poorly-defined, mixed-density lesion (7.0&#xa0;cm &#xd7; 7.1&#xa0;cm) with internal enhancement involving the right hepatic lobe, suggestive of hepatic malignancy (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). In the delayed venous phase, both the portal vein and inferior vena cava were patent.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>
<bold>(A, B)</bold> Contrast-enhanced computed tomography scan of the abdomen revealing a poorly-defined, mixed-density lesion (7.0&#xa0;cm &#xd7; 7.1&#xa0;cm) with internal enhancement involving the right hepatic lobe, initially considered as hepatic malignancy.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1376276-g001.tif"/>
</fig>
<p>Magnetic resonance imaging (MRI) of the abdomen displayed a 10&#xa0;cm &#xd7; 7.6&#xa0;cm, contrast-enhancing, poorly defined, large-size lesion affecting the right hepatic lobe, also indicative of hepatic malignancy (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>
<bold>(A, B)</bold> Magnetic resonance imaging (MRI) of the abdomen displaying a 10&#xa0;cm &#xd7; 7.6&#xa0;cm, contrast-enhancing, poorly defined, large-sized lesion involving the right hepatic lobe, also initially considered as hepatic malignancy.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1376276-g002.tif"/>
</fig>
<p>Ultrasound of bilateral lacrimal gland, salivary gland, parotid gland, submandibular gland, and thyroid did not show enlarged glandular. Ultrasound of retroperitoneum, pancreas, bile duct, kidney, and spleen showed no abnormalities. Superficial lymph node ultrasound showed enlarged lymph nodes in both necks, with the largest being about 18&#xd7;7mm on the left side, 19&#xd7;8mm on right side, several small lymph nodes under both armpits, with the largest being about 7&#xd7;3mm, several lymph nodes in bilateral inguinal region, with the largest being about 8&#xd7;3mm. The lymph nodes were with clear boundaries between the cortex and medulla. CT of pulmonary suggested infection and diffuse interstitial changes in both lungs. No abnormalities were found in the MRI of the orbit, head, and pituitary gland.</p>
<p>Ultrasonography (US)-guided percutaneous needle biopsy (Pro&#x2022;Mag&#x2122;, 18 gauge, 10&#xa0;cm, Athens, TX75751, USA) was performed on the hepatic mass. Histopathological analysis revealed dense fibrous tissue around the portal area in storiform, along with a mixture of inflammatory cells and eosinophil infiltration in the portal area (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Obliterating phlebitis was observed, while lymphoid follicles were absent (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). The biopsy showed no granulomas or necrotic areas. Immunohistochemically, the inflammatory cells stained diffusely positive for CD38 and Mum-1 (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures 1A, B</bold>
</xref>), indicative of plasma cells. Additionally, the hepatic lesion displayed focal positivity for IgG4 [&gt; 10 plasma cells/high-power field(HPF)] (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures 1C, D</bold>
</xref>), with a ratio of IgG4/IgG plasma cells exceeding 40%, meeting the criteria for classification as an IgG4-related disease. The serum IgG4 concentration was markedly elevated at 1542.2 mg/L (normal range: 10-537 mg/L).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>
<bold>(A, B)</bold> Microscopic image of the focal hepatic lesion showing a mixture of inflammatory cells in a background of dense fibrous tissues (HE stain, magnification power: &#xd7;200).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1376276-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Microscopic picture of the focal hepatic lesion displaying obliterating phlebitis (He stain, magnification power, &#xd7;200).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1376276-g004.tif"/>
</fig>
<p>Based on a history of recurrent respiratory tract infections, CT of pulmonary, and elevated levels of fungal D-glucan, we considered that the lung lesions of the patient in our case is fungal pneumonia. After 2 weeks of treatment with voriconazole, CT of pulmonary showed significant improvement and fungal D-glucan levels decreased to normal. Upon integration of the clinical and radiological features, serum IgG4 levels, and pathological features, a conclusive diagnosis of IgG4-related hepatic IPT(lymphoplasmacytic type) was established. Subsequently, treatment commenced with mycophenolate mofetil (0.25g/day) and prednisone (1mg/Kg/day). At the 8-month postoperative of liver biopsy follow-up, the patient remained afebrile and asymptomatic, with ultrasound evidence indicating a reduction in hepatic mass (2.9&#xa0;cm &#xd7; 2.3&#xa0;cm &#xd7; 1.8&#xa0;cm) and an increase in hemoglobin levels (112g/L at 8 months).</p>
</sec>
<sec id="s3" sec-type="discussion">
<label>3</label>
<title>Discussion</title>
<p>IgG4-RD represents a rare fibroinflammatory disorder associated with chronic, yet unidentified, antigenic stimulation. Up until 2022, a mere 22 cases of pediatric IgG4-RD have been documented, with the median age at initial symptom onset reported as 13 years (ranging from 22 months to 17 years) (<xref ref-type="bibr" rid="B6">6</xref>). Within the spectrum of diverse organ manifestations observed in pediatric IgG4-RD, the occurrence of IgG4-related hepatic inflammatory pseudotumor as an organ manifestation has been delineated in only one prior case report involving a ten-year-old child (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The present report contributes to the limited literature on pediatric IgG4-RD by detailing the case of a 3-year-old boy exhibiting hepatic inflammatory pseudotumor as a manifestation of IgG4-RD.</p>
<p>The symptoms of IgG4-RD are variable and contingent on the affected organs. However, the clinical presentation of hepatic IPT is characterized by nonspecific features, including abdominal pain, fever, weight loss, and general fatigue, which commonly lead patients to seek evaluations across various departments in pursuit of a diagnosis (<xref ref-type="bibr" rid="B9">9</xref>).We listed the past IgG4-related IPT involving liver in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> details previous cases of IgG4-related inflammatory pseudotumors involving the liver (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). Specifically, the patient in this report exhibited leading symptoms of anemia, fever, and a tender hepatic mass within the hematology department. Laboratory examination of the anemia revealed hypochromic microcytic anemia. The reason for anemia was considered to chronic consumption of the gigantic hepatic mass of the patient. The final reason remains to be further studied. Notably, two cases in children reported by Wiegering et&#xa0;al. emphasized anemia as a primary symptom for hepatic IPT (<xref ref-type="bibr" rid="B17">17</xref>), with hypochromic microcytic anemia, a laboratory indicator of an inflammatory response, also documented in pediatric hepatic IPT cases (<xref ref-type="bibr" rid="B18">18</xref>). The presentation of our case contributes to raising awareness of IgG4 RD in pediatrics, particularly among hematologists.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Studies reporting on IgG4-related inflammatory pseudotumor involving liver.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Reference</th>
<th valign="top" align="center">Age</th>
<th valign="top" align="center">Gender</th>
<th valign="top" align="center">Tumor site</th>
<th valign="top" align="center">Prognosis</th>
<th valign="top" align="center">Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">Itazaki Y 2021 (<xref ref-type="bibr" rid="B10">10</xref>)<break/>Kim F 2011 (<xref ref-type="bibr" rid="B11">11</xref>)<break/>Shibata M 2016 (<xref ref-type="bibr" rid="B5">5</xref>)<break/>Miyajima S 2017 (<xref ref-type="bibr" rid="B12">12</xref>)<break/>Okamura Y 2021 (<xref ref-type="bibr" rid="B13">13</xref>)<break/>Mulki R 2015 (<xref ref-type="bibr" rid="B14">14</xref>)<break/>Kanno A 2005 (<xref ref-type="bibr" rid="B15">15</xref>)<break/>Lee JH 2018 (<xref ref-type="bibr" rid="B16">16</xref>)</td>
<td valign="top" align="center">75y<break/>58y<break/>72y<break/>50y<break/>67y<break/>50y<break/>48y<break/>67y</td>
<td valign="top" align="center">F<break/>M<break/>M<break/>F<break/>M<break/>M<break/>M<break/>M</td>
<td valign="top" align="center">Left liver<break/>Kidney and Liver<break/>Liver<break/>Liver and abdominal wall<break/>Left hepatic umbilical portion<break/>Left liver<break/>Liver<break/>Liver</td>
<td valign="top" align="center">IgG-R IPT<break/>IgG-R IPT<break/>IgG-R IPT<break/>IgG-R IPT<break/>IgG4-SC<break/>IgG-R IPT<break/>AIP with IP<break/>IgG4-R pseudotumor</td>
<td valign="top" align="center">Surgical excisions<break/>Prednisolone<break/>Corticosteroids<break/>Corticosteroids<break/>Surgical excisions<break/>Surgical excisions<break/>Corticosteroids<break/>Steroid and ursodeoxycholic acid tablet</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Y, year; M, male; F, female; IgG-R IPT, IgG4-related inflammatory pseudotumor; IgG4-SC, IgG4-related sclerosing cholangitis; AIP, autoimmune pancreatitis; IP, inflammatory pseudotumor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The initial misdiagnosis in our case stemmed from the nonspecific nature of the clinical presentation and radiological findings. Discriminating hepatic IPT from malignant tumors, particularly in children given their rare incidence, poses a significant challenge. Based on the CT and MRI results, we initially categorized the hepatic mass in this case as hepatic malignancy (<xref ref-type="bibr" rid="B19">19</xref>). Similarly, contrast-enhanced MRI images of hepatic IPTs in adults have exhibited similarities to hepato-cholangiocarcinomas (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). However, misclassifying hepatic IPTs as malignant tumors may lead to unnecessary surgical interventions (<xref ref-type="bibr" rid="B22">22</xref>), underscoring the critical importance of accurate diagnosis.</p>
<p>The definitive diagnosis of IPT relies on pathological examination. Hepatic IPTs can be pathologically categorized into fibrohistiocytic and lymphoplasmacytic types. The lymphoplasmacytic type, characterized by diffuse lymphoplasmacytic infiltration with numerous IgG4-positive plasma cells, is associated with IgG4-RD (<xref ref-type="bibr" rid="B1">1</xref>).The 2020 revised comprehensive diagnostic criteria for IgG4-RD consists of three major items: 1) one or more organs show diffuse or localized swelling or a mass or nodule characteristic of IgG4-RD; 2) elevated serum IgG4 concentrations greater than 135 mg/dl; 3) dense lymphocyte and plasma cell infiltration, defined as &gt; 10 IgG4+ cells per HPF and a &gt; 40% ration of IgG4+/IgG+ cells, accompanied by fibrosis and typical tissue fibrosis, particularly storiform fibrosis, or obliterative phlebitis (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). In our case, a hepatic mass was found, and the serum IgG4 concentration in our case was elevated at 154mg/dl, surpassing the threshold of &gt; 135 mg/dl. Additionally, the pathological features of our cases were consistent with IgG4-RD. The amalgamation of hepatic mass, serum IgG4 concentration, and pathological features led to the diagnosis of IgG4-related hepatic IPT. Besides, the patient presented swelling of multiple superfical lymph nodes in our case. Due to the presence of fungal pneumonia in the patient, multiple superficial lymphadenopathy may be associated with infection. However, since we did not perform pathological biopsies on these lymph nodes, we cannot completely rule out IgG4 related lymph node diseases.</p>
<p>The differential diagnosis of IPT encompasses various conditions, including infection, inflammatory myofibroblastic tumor (IMT), IPT-like follicular dendritic cell (FDC) tumor, inflammatory angiomyolipoma, lymphoma, and inflammatory hepatocellular carcinoma (<xref ref-type="bibr" rid="B25">25</xref>). Infections typically manifest with clinical signs such as fever, elevated neutrophil counts, multifocality, and responsiveness to antibiotics. IMT, often initially misdiagnosed as IPT due to similar constitutional symptoms and gross features, accounts for less than 10% of IMTs, and the number of IgG4-positive plasma cells and the IgG4:IgG ratio in IMT are lower than the threshold for IgG-RD. Additionally, the inflammatory infiltrate in IMT is less prominent in peritumoral tissue (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>). Historically, EBV-positive FDC tumor was considered a subtype of IPT in the 1990s due to similar histological characteristics (<xref ref-type="bibr" rid="B29">29</xref>). However, EBV expression is now recognized as a sensitive screening method for distinguishing IPT from FDC tumor. In cases of acute myelocytic leukemia(AML) with spindled myocytes, the heavy but variable infiltrate of lymphocytes, plasma cells, and histiocytes can mimic IPT. However, AML is rarely found in the liver, and hepatic AML rarely exhibits exuberant inflammation (<xref ref-type="bibr" rid="B30">30</xref>). Hodgkin lymphoma can sometimes mimic IPT, but lymphoma patients rarely present with hepatic involvement. The presence of scattered large atypical lymphoid cells and markers for B-cells are apparent differences between lymphoma and IPT (<xref ref-type="bibr" rid="B31">31</xref>). In the case of inflammatory hepatocellular carcinoma, a biopsy from a region with a paucity of neoplastic cells and massive infiltration of immune cells may resemble an IPT. Immunohistochemical results can help distinguish inflammatory hepatocellular carcinoma from hepatic IPT (<xref ref-type="bibr" rid="B25">25</xref>). Considering the clinical signs, the number of IgG4-positive plasma cells, the IgG4:IgG ratio, negative EBV expression, and the inflammatory infiltrate in our case, we successfully ruled out infections and neoplasms that mimic hepatic IPT.</p>
<p>In the management of IgG4-RD, corticosteroids stand as the primary therapeutic approach, showcasing dramatic clinical responses in the majority of cases (<xref ref-type="bibr" rid="B32">32</xref>). The recommended corticosteroid regimen involves prednisolone or prednisone at a dose of 0.4-0.6 mg/kg/d for 3-4 weeks, gradually tapering down for maintenance treatment (<xref ref-type="bibr" rid="B33">33</xref>). However, a notable tendency to relapse during the maintenance phase has been observed (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Studies suggest that low-dose corticosteroids administered for 1-3 years may reduce the relapse rate (<xref ref-type="bibr" rid="B32">32</xref>). Nevertheless, recent reports on adverse events associated with corticosteroids have constrained their long-term use in IgG4-RD (<xref ref-type="bibr" rid="B36">36</xref>). Consequently, the combination of corticosteroids with immunosuppressive agents (IM) has been contemplated for its potential to yield higher remission rates and lower relapse rates compared to corticosteroid monotherapy (<xref ref-type="bibr" rid="B37">37</xref>). Mycophenolate mofetil and azathioprine are the most widely used IM in clinical practice (<xref ref-type="bibr" rid="B38">38</xref>).A randomized clinical trial showed efficacy and safety of glucocorticoid combined with mycophenolate mofetil therapy for IgG4-RD (<xref ref-type="bibr" rid="B39">39</xref>). For this reason, the treatment regimen for the patient in this case involved prednisone in combination with mycophenolate mofetil. Remarkably, the patient exhibited resolution of fever, reduction in the size of the hepatic mass, improvement in markers of inflammation (i.e., ESR and CRP level), and a decline in serum IgG4 levels (665.5 mg/L, normal range: 10-537 mg/L) over an 8-month follow-up period.</p>
<p>Concerning the prognosis, studies indicate that the recurrence rate of IgG4-RD during the follow-up period ranges from 24% to 63%, with variations noted in different investigations (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). A recent study employing Cox regression analysis identified several factors significantly associated with relapse, including higher baseline serum IgG4 concentrations (&gt; 27000 mg/L), baseline elevation of serum eosinophils, multi-organ involvement (more than four organs), lymph node involvement, and higher RI scores (<xref ref-type="bibr" rid="B24">24</xref>). Notably, a history of recurrence and severe disease manifestations on imaging are indicative of a higher likelihood of relapse (<xref ref-type="bibr" rid="B42">42</xref>). Considering the results of the patient in our report, the favorable outcomes observed, including resolution of symptoms, reduction in the size of the hepatic mass, and improvements in inflammatory markers and serum IgG4 levels, suggest a potentially favorable nonrelapsed prognosis.</p>
</sec>
<sec id="s4" sec-type="conclusions">
<label>4</label>
<title>Conclusion</title>
<p>In this report, we present a case of IgG4-related hepatic IPT. The challenges in diagnosis underscore the necessity and complexity of differential diagnosis in patients with a hepatic mass. Histopathological examination remains pivotal for confirming IgG4-related hepatic IPT. In our case, anemia emerged as the primary and non-atypical clinical symptom. Despite the rarity of IgG4-related hepatic IPT, particularly in children, comprehensive testing is imperative to either rule out or confirm the diagnosis when confronted with an unidentified hepatic mass.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Ethics Committee of Jiangxi Provincial Children&#x2019;s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)&#x2019; legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>QW: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. ZX: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. XL: Writing &#x2013; review &amp; editing. ZW: Writing &#x2013; review &amp; editing. QZ: Writing &#x2013; review &amp; editing. CW: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1376276/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1376276/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image_1.jpeg" id="SM1" mimetype="image/jpeg">
<label>Supplementary Figure 1</label>
<caption>
<p>Immunohistochemical analysis of the focal hepatic lesion. All inflammatory cells in the lesion stained diffusely positive for CD38 (<bold>A</bold>, CD38 stain, magnification power: &#xd7;200) and Mum-1 (<bold>B</bold>, Mum-1 stain, magnification power: &#xd7;200), indicative of plasma cells. Plasma cells were positive for IgG (<bold>C</bold>, IgG stain, magnification power: &#xd7;200), with a few plasma cells in the lesion showing focal positivity for IgG4 (&gt;10 plasma cells/high-power field) (<bold>D</bold>, IgG4 stain, magnification power: &#xd7;200). The ratio of IgG4/IgG plasma cells was &gt;40%.</p>
</caption>
</supplementary-material>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr">
<p>IPT, Inflammatory Pseudotumor; IgG4-RD, IgG4-related diseases; IgG4, immunoglobulin G4; ESR, erythrocyte sedimentation rate; IgG, immunoglobulin G; CRP, C-reactive protein; EBV, Epstein-Barr virus; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CT, Contrast-enhanced computed tomography; MRI, Magnetic resonance imaging; US, Ultrasonography; HPF, high powered field; IMT, inflammatory myofibroblastic tumor; FDC, follicular dendritic cell; AML, acute myelocytic leukemia; IM, immunosuppressive gents.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fujii</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Masuda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nakanuma</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease</article-title>. <source>Mod Pathol</source>. (<year>2007</year>) <volume>20</volume>:<page-range>884&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/modpathol.3800836</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Harada</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tsuneyama</surname> <given-names>K</given-names>
</name>
<name>
<surname>Haratake</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis</article-title>? <source>Am J Surg Pathol</source>. (<year>2004</year>) <volume>28</volume>:<page-range>1193&#x2013;203</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.pas.0000136449.37936.6c</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Culver</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Chapman</surname> <given-names>RW</given-names>
</name>
</person-group>. <article-title>IgG4-related hepatobiliary disease: an overview</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. (<year>2016</year>) <volume>13</volume>:<page-range>601&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrgastro.2016.132</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Hussaini</surname> <given-names>H</given-names>
</name>
<name>
<surname>Azouz</surname> <given-names>H</given-names>
</name>
<name>
<surname>Abu-Zaid</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Hepatic inflammatory pseudotumor presenting in an 8-year-old boy: A case report and review of literature</article-title>. <source>World J Gastroenterol</source>. (<year>2015</year>) <volume>21</volume>:<page-range>8730&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3748/wjg.v21.i28.8730</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibata</surname> <given-names>M</given-names>
</name>
<name>
<surname>Matsubayashi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Aramaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Uesaka</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tsutsumi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>A case of IgG4-related hepatic inflammatory pseudotumor replaced by an abscess after steroid treatment</article-title>. <source>BMC Gastroenterol</source>. (<year>2016</year>) <volume>16</volume>:<fpage>89</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12876-016-0504-6</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Sainte</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Ebbo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Grados</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rebours</surname> <given-names>V</given-names>
</name>
<name>
<surname>Reumaux</surname> <given-names>H</given-names>
</name>
<name>
<surname>Briantais</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A descriptive study of IgG4-related disease in children and young adults</article-title>. <source>Autoimmun Rev</source>. (<year>2022</year>) <volume>21</volume>:<elocation-id>103035</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.autrev.2022.103035</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karim</surname> <given-names>F</given-names>
</name>
<name>
<surname>Loeffen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bramer</surname> <given-names>W</given-names>
</name>
<name>
<surname>Westenberg</surname> <given-names>L</given-names>
</name>
<name>
<surname>Verdijk</surname> <given-names>R</given-names>
</name>
<name>
<surname>van Hagen</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>IgG4-related disease: a systematic review of this unrecognized disease in pediatrics</article-title>. <source>Pediatr Rheumatol Online J</source>. (<year>2016</year>) <volume>14</volume>:<elocation-id>18</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12969-016-0079-3</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nada</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rawat</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sood</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ahluwalia</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatic mass and coagulopathy in a ten-year-old boy with fever</article-title>. <source>Arthritis Rheumatol</source>. (<year>2015</year>) <volume>67</volume>:<fpage>1977</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.39131</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imazu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Shibata</surname> <given-names>M</given-names>
</name>
<name>
<surname>Koya</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Morino</surname> <given-names>K</given-names>
</name>
<name>
<surname>Honma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Senju</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatic inflammatory pseudotumor protruding from the liver surface and directly penetrating the colon</article-title>. <source>Intern Med</source>. (<year>2020</year>) <volume>59</volume>:<page-range>527&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2169/internalmedicine.3599-19</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itazaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Einama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Konno</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fujinuma</surname> <given-names>I</given-names>
</name>
<name>
<surname>Takihata</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Iwasaki</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>IgG4-related hepatic inflammatory pseudotumor mimicking cholangiolocellular carcinoma</article-title>. <source>Clin J Gastroenterol</source>. (<year>2021</year>) <volume>14</volume>:<page-range>1733&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12328-021-01526-z</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname> <given-names>D</given-names>
</name>
<name>
<surname>Nakajima</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mizushima</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kakuchi</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>IgG4-related tubulointerstitial nephritis and hepatic inflammatory pseudotumor without hypocomplementemia</article-title>. <source>Intern Med</source>. (<year>2011</year>) <volume>50</volume>:<page-range>1239&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2169/internalmedicine.50.5102</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyajima</surname> <given-names>S</given-names>
</name>
<name>
<surname>Okano</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ohana</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Immunoglobulin G4-related hepatic inflammatory pseudotumor invading the abdominal wall</article-title>. <source>Clin J Gastroenterol</source>. (<year>2017</year>) <volume>10</volume>:<fpage>57</fpage>&#x2013;<lpage>62</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12328-016-0701-4</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nishitai</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>N</given-names>
</name>
<name>
<surname>An</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fushitani</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ota</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Intrahepatic bile duct rupture associated with IgG4-related sclerosing cholangitis presenting hepatic inflammatory pseudotumor</article-title>. <source>Clin J Gastroenterol</source>. (<year>2021</year>) <volume>14</volume>:<page-range>1530&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12328-021-01487-3</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulki</surname> <given-names>R</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Manatsathit</surname> <given-names>W</given-names>
</name>
<name>
<surname>Miick</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>IgG4-related inflammatory pseudotumour mimicking a hepatic abscess impending rupture</article-title>. <source>BMJ Case Rep</source>. (<year>2015</year>) <volume>2015</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bcr-2015-211893</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname> <given-names>A</given-names>
</name>
<name>
<surname>Satoh</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Masamune</surname> <given-names>A</given-names>
</name>
<name>
<surname>Asakura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Unno</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Autoimmune pancreatitis with hepatic inflammatory pseudotumor</article-title>. <source>Pancreas</source>. (<year>2005</year>) <volume>31</volume>:<page-range>420&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.mpa.0000179732.46210.da</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>Hepatic actinomycosis with immunoglobulin G4-related liver disease: A case report</article-title>. <source>Med (Baltimore)</source>. (<year>2018</year>) <volume>97</volume>:<fpage>e11146</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MD.0000000000011146</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiegering</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>I</given-names>
</name>
<name>
<surname>Wirth</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dick</surname> <given-names>A</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Schlegel</surname> <given-names>PG</given-names>
</name>
<etal/>
</person-group>. <article-title>Anemia and B symptoms as leading symptoms for a hepatic inflammatory pseudotumor&#x2013;2 case reports</article-title>. <source>Klin Padiatr</source>. (<year>2015</year>) <volume>227</volume>:<page-range>363&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1055/s-0034-1395693</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karnak</surname> <given-names>I</given-names>
</name>
<name>
<surname>Senocak</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Ciftci</surname> <given-names>AO</given-names>
</name>
<name>
<surname>Caglar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bingol-Kologlu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tanyel</surname> <given-names>FC</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory myofibroblastic tumor in children: diagnosis and treatment</article-title>. <source>J Pediatr Surg</source>. (<year>2001</year>) <volume>36</volume>:<page-range>908&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/jpsu.2001.23970</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geramizadeh</surname> <given-names>B</given-names>
</name>
<name>
<surname>Bahador</surname> <given-names>A</given-names>
</name>
<name>
<surname>Foroutan</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Banani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nikeghbalian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Malek-Hosseini</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>Pathology of pediatric liver tumors, a single center experience from south of Iran</article-title>. <source>Indian J Pathol Microbiol</source>. (<year>2010</year>) <volume>53</volume>:<page-range>422&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/0377-4929.68258</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>IgG4-related hepatic inflammatory pseudotumor misdiagnosed as cholangiocellular carcinoma of the liver</article-title>. <source>J Gastrointest Surg</source>. (<year>2021</year>) <volume>25</volume>:<page-range>1065&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11605-019-04405-8</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamano</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kurata</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tsuboi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Inoue</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Difficulty in differentiating between IgG4-related hepatic inflammatory pseudotumor and intrahepatic cholangiocarcinoma</article-title>. <source>Clin J Gastroenterol</source>. (<year>2021</year>) <volume>14</volume>:<page-range>263&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12328-020-01245-x</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koea</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Broadhurst</surname> <given-names>GW</given-names>
</name>
<name>
<surname>Rodgers</surname> <given-names>MS</given-names>
</name>
<name>
<surname>McCall</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Inflammatory pseudotumor of the liver: demographics, diagnosis, and the case for nonoperative management</article-title>. <source>J Am Coll Surg</source>. (<year>2003</year>) <volume>196</volume>:<page-range>226&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1072-7515(02)01495-3</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umehara</surname> <given-names>H</given-names>
</name>
<name>
<surname>Okazaki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kawa</surname> <given-names>S</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Goto</surname> <given-names>H</given-names>
</name>
<name>
<surname>Matsui</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD</article-title>. <source>Mod Rheumatol</source>. (<year>2021</year>) <volume>31</volume>:<page-range>529&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/14397595.2020.1859710</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umehara</surname> <given-names>H</given-names>
</name>
<name>
<surname>Okazaki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Masaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kawano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yamamoto</surname> <given-names>M</given-names>
</name>
<name>
<surname>Saeki</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011</article-title>. <source>Mod Rheumatol</source>. (<year>2012</year>) <volume>22</volume>:<fpage>21</fpage>&#x2013;<lpage>30</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10165-011-0571-z</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Misdraji</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Inflammatory pseudotumor of the liver</article-title>. <source>Surg Pathol Clin</source>. (<year>2023</year>) <volume>16</volume>:<page-range>565&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.path.2023.04.010</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coffin</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Watterson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Priest</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Dehner</surname> <given-names>LP</given-names>
</name>
</person-group>. <article-title>Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases</article-title>. <source>Am J Surg Pathol</source>. (<year>1995</year>) <volume>19</volume>:<page-range>859&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00000478-199508000-00001</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gleason</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Hornick</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Inflammatory myofibroblastic tumours: where are we now</article-title>? <source>J Clin Pathol</source>. (<year>2008</year>) <volume>61</volume>:<page-range>428&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jcp.2007.049387</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yamaguchi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Aishima</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oda</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kohashi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Oshiro</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study</article-title>. <source>Am J Surg Pathol</source>. (<year>2009</year>) <volume>33</volume>:<page-range>1330&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/pas.0b013e3181a5a207</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arber</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Weiss</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>Detection of Epstein-Barr Virus in inflammatory pseudotumor</article-title>. <source>Semin Diagn Pathol</source>. (<year>1998</year>) <volume>15</volume>:<page-range>155&#x2013;60</page-range>.</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsui</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Colombari</surname> <given-names>R</given-names>
</name>
<name>
<surname>Portmann</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Bonetti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Thung</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Ferrell</surname> <given-names>LD</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants</article-title>. <source>Am J Surg Pathol</source>. (<year>1999</year>) <volume>23</volume>:<fpage>34</fpage>&#x2013;<lpage>48</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00000478-199901000-00004</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname> <given-names>WT</given-names>
</name>
<name>
<surname>Gill</surname> <given-names>RM</given-names>
</name>
</person-group>. <article-title>Hepatic lymphoma diagnosis</article-title>. <source>Surg Pathol Clin</source>. (<year>2018</year>) <volume>11</volume>:<fpage>389</fpage>&#x2013;<lpage>402</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.path.2018.02.003</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khosroshahi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wallace</surname> <given-names>ZS</given-names>
</name>
<name>
<surname>Crowe</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Akamizu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Azumi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Carruthers</surname> <given-names>MN</given-names>
</name>
<etal/>
</person-group>. <article-title>International consensus guidance statement on the management and treatment of igG4-related disease</article-title>. <source>Arthritis Rheumatol</source>. (<year>2015</year>) <volume>67</volume>:<page-range>1688&#x2013;99</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.39132</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Kamisawa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Brugge</surname> <given-names>WR</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Culver</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Czako</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis</article-title>. <source>Gut</source>. (<year>2013</year>) <volume>62</volume>:<page-range>1771&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/gutjnl-2012-303617</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallace</surname> <given-names>ZS</given-names>
</name>
<name>
<surname>Mattoo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mahajan</surname> <given-names>VS</given-names>
</name>
<name>
<surname>Kulikova</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Deshpande</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors of disease relapse in IgG4-related disease following rituximab</article-title>. <source>Rheumatol (Oxford)</source>. (<year>2016</year>) <volume>55</volume>:<page-range>1000&#x2013;08</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rheumatology/kev438</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname> <given-names>J</given-names>
</name>
<name>
<surname>Barkin</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Barkin</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis</article-title>. <source>Gut</source>. (<year>2018</year>) <volume>67</volume>:<fpage>591</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/gutjnl-2017-314460</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takikawa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kikuta</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sano</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ikeura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Fujimori</surname> <given-names>N</given-names>
</name>
<name>
<surname>Umemura</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Maintenance steroid therapy is associated with decreased risk of Malignancy and better prognosis of patients with autoimmune pancreatitis: A multicenter cohort study in Japan</article-title>. <source>Pancreatology</source>. (<year>2024</year>) <volume>24</volume>: <page-range>335&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pan.2024.01.008</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Omar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis</article-title>. <source>Rheumatol (Oxford)</source>. (<year>2020</year>) <volume>59</volume>:<page-range>718&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rheumatology/kez380</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>XF</given-names>
</name>
<etal/>
</person-group>. <article-title>[Chinese expert consensus on the diagnosis and treatment of IgG(4) related diseases]</article-title>. <source>Zhonghua Nei Ke Za Zhi</source>. (<year>2021</year>) <volume>60</volume>:<fpage>192</fpage>&#x2013;<lpage>206</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3760/cma.j.cn112138-20200803-00726</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yunyun</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Panpan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Linyi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Jiaxin</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial</article-title>. <source>Rheumatol (Oxford)</source>. (<year>2019</year>) <volume>58</volume>:<fpage>52</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rheumatology/key227</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>JQ</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>PP</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study</article-title>. <source>J Intern Med</source>. (<year>2019</year>) <volume>286</volume>:<page-range>542&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/joim.12942</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort</article-title>. <source>Rheumatol (Oxford)</source>. (<year>2020</year>) <volume>59</volume>:<page-range>2115&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rheumatology/kez669</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Bian</surname> <given-names>W</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease</article-title>. <source>Clin Rheumatol</source>. (<year>2020</year>) <volume>39</volume>:<page-range>491&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10067-019-04880-z</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>